arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

TransMedics Group, Inc.

TMDX
$83.92 ▲ +3.68 (+4.59%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
34 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
83
Health
Excellent
Bullish
auto_awesome

Analytical Summary

TransMedics Group, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $2.9B
Dividend Yield
Revenue Growth 21.2%
Op. Margin 7.6%
ROIC 2.3%
FCF / Share $-0.35
Trailing P/E 399.6x
Price / Book 5.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

34-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$173.93M
↑ +21.2%
Net Income Profit after all expenses
$7.32M
↓ -71.5%
Operating Margin Operating profit as % of sales
7.6%
↓ -42.2% 72th
FCF / Share Free cash flow per share
$-0.35
↑ +60.2%
Long-Term Debt Long-term obligations
$58.80M
— +0.4%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
83
Returns
96
Financial Health
83
Cash Quality
49

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters